These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 26133247)
21. VITRECTOMY FOR PERSISTENT MACULAR HOLES FOLLOWING OCRIPLASMIN INJECTION: A Comparative Multicenter Study. Schumann RG; Wolf A; Hoerauf H; Lommatzsch A; Maier M; Wachtlin J; Koss MJ; Kreutzer T; Bertelmann T; Kazerounian S; Mennel S; Priglinger SG Retina; 2017 Dec; 37(12):2295-2303. PubMed ID: 28098729 [TBL] [Abstract][Full Text] [Related]
22. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin. Moisseiev J; Moroz I; Katz G JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009 [TBL] [Abstract][Full Text] [Related]
23. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole. Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816 [No Abstract] [Full Text] [Related]
24. IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY. Paul C; Heun C; Müller HH; Fauser S; Kaymak H; Kazerounian S; Sekundo W; Mennel S; Meyer CH; Schmitz-Valckenberg S; Koss MJ; Feltgen N; Bertelmann T Retina; 2017 Jul; 37(7):1252-1260. PubMed ID: 27787446 [TBL] [Abstract][Full Text] [Related]
25. Ultrastructure of the vitreomacular interface in full-thickness idiopathic macular holes: a consecutive analysis of 100 cases. Schumann RG; Schaumberger MM; Rohleder M; Haritoglou C; Kampik A; Gandorfer A Am J Ophthalmol; 2006 Jun; 141(6):1112-1119. PubMed ID: 16765681 [TBL] [Abstract][Full Text] [Related]
26. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555 [TBL] [Abstract][Full Text] [Related]
27. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Gandorfer A; Rohleder M; Grosselfinger S; Haritoglou C; Ulbig M; Kampik A Am J Ophthalmol; 2005 Apr; 139(4):638-52. PubMed ID: 15808159 [TBL] [Abstract][Full Text] [Related]
28. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection. Abou Ltaif S; Herbert L BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463 [TBL] [Abstract][Full Text] [Related]
29. EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS. Bormann C; Apitzsch BC; Habermann A; Hammer U; Hammer T Retin Cases Brief Rep; 2020; 14(4):377-380. PubMed ID: 29621042 [TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823 [TBL] [Abstract][Full Text] [Related]